Department

Pharmacy Practice

Home Academics Departments Faculty Thomas Lodise, PharmD, PhD

Professor
Focus: Infectious Disease
518-694-7292
thomas.lodise@zhuaren.net


Speaker Request
Thomas Lodise, PharmD, PhD

Education

  • Ph.D. in Epidemiology, University at Albany
  • Pharm.D., Temple University School of Pharmacy

Courses Taught at ACPHS

  • Drug Information (study design and statistics)
  • Epidemiology I
  • Epidemiology II

Research Interests

  • Integrating his dual interests in scholarship and patient care, Dr. Lodise的总体研究目标是定量地提高我们目前对侵袭性细菌感染患者抗菌药物暴露-反应关系的理解. His research encompasses three interrelated domains: pharmacokinetics (PK)/pharmacodynamics (PD), epidemiology, and outcomes.
  • His specific research objectives are 4-fold: develop “personalized” patient care strategies that improve outcomes; reduce the likelihood of drug-induced toxicities; minimize the emergence of antibiotic resistant infections; and reduce healthcare costs. In short, his research works to define the “right antibiotic at the right dose for the right patient.”
  • Research cannot improve patient care unless the knowledge is transferable. To this end, 他采用尖端的数学建模技术来识别患者和治疗相关的因素，促进以患者为中心的最佳结果.  先进的药物流行病学和比较有效性方法也被用于确定抗生素耐药感染患者的最佳经验性和针对性治疗策略. In addition, 他使用最先进的PK/PD方法来设计抗生素剂量方案，以优化疗效并最大限度地减少药物毒性，以便在临床实践中实施. 他对确定在III期临床中代表性不足的患者群体的最佳给药方案特别感兴趣.  
  • To date, he has published over 100 peer-reviewed articles in reputable scientific journals, including Clinical Infectious Diseases, Antimicrobial Agents and Chemotherapy, Lancet Infectious Diseases, Chest, and Journal of Antimicrobial Chemotherapy. He has also secured over $1.5 million in grant funding from various sources.

Recognition

  • New York Chapter of American College of Clinical Pharmacy Researcher of the Year (2015)
  • Society of Infectious Diseases Pharmacists (SIDP) Impact Paper of the Year (2015) 
  • Researcher of the Year (First Inaugural) Albany College of Pharmacy and Health Sciences (2013)
  • Clinical Infectious Diseases Award for Outstanding Journal Article Review (2010)
  • Society of Infectious Diseases Pharmacists (SIDP) Impact Paper of the Year (2010)
  • Clinical Infectious Diseases Award for Outstanding Journal Article Review (2009)
  • Society of Infectious Diseases Pharmacists (SIDP) Young Investigator of the Year (2008)
  • Clinical Infectious Diseases Award for Outstanding Journal Article Review (2007)
  • 美国临床药学学院(ACCP)传染病PRN和ACCP研究所传染病PRN迷你休假导师(2007)
  • New York Chapter of American College of Clinical Pharmacy Researcher of the Year (2006)
  • 美国临床药学学院(ACCP)传染病PRN和ACCP研究所传染病PRN迷你休假导师(2005)

Hospital Affiliation

  • Dr. Lodise is a Clinical Pharmacist at the Stratton VA Medical Center in Albany, NY.

Selected Publications

Publications

Bonine NG, Berger A, Altincatal A, Wang R, Bhagnani T, Gillard P, Lodise T. 延迟适当抗生素治疗对严重革兰氏阴性细菌感染患者抗生素耐药状况的影响. The American Journal of the Medical Sciences 2019 Feb;357(2):103-110. doi: 10.1016/j.amjms.2018.11.009. Epub 2018 Nov 22. PubMed PMID: 30665490.

Tartof SY, Kuntz JL, Chen LH, Wei R, Puzniak L, Tian Y, Im TM, Takhar HS, Merchant S, Lodise T. 铜绿假单胞菌感染成人住院患者碳青霉烯类和广泛β-内酰胺耐药风险评分的制定与评估. JAMA Network Open 2018 Oct 5;1(6):e183927. doi: 10.1001/jamanetworkopen.2018.3927. PubMed PMID: 30646267; PubMed Central PMCID: PMC6324445.

Hardalo C, Lodise TP, De Anda C. Myelosuppression with Oxazolidinones: Are There Differences? Antimicrobial Agents and Chemotherapy 2018 Dec 21;63(1). pii: e01833-18. doi: 10.1128/AAC.01833-18. Print 2019 Jan. PubMed PMID: 30578404.

Rank EL, Lodise T, Avery L, Bankert E, Dobson E, Dumyati G, Hassett S, Keller M, Pearsall M, Lubowski T, Carreno JJ. Antimicrobial Susceptibility Trends Observed in Urinary Pathogens Obtained From New York State. Open Forum Infectious Diseases 2018 Nov 16;5(11):ofy297. doi: 10.1093/ofid/ofy297. eCollection 2018 Nov. PubMed PMID: 30539040; PubMed Central PMCID: PMC6284462.

Lodise TP, Zhao Q, Fahrbach K, Gillard PJ, Martin A. 对肺炎克雷伯菌或大肠杆菌感染住院患者延迟适当治疗与死亡率之间关系的系统回顾:多长时间太长? BMC Infect Diseases 2018 Dec 5;18(1):625. doi: 10.1186/s12879-018-3524-8. PubMed PMID: 30518337; PubMed Central PMCID: PMC6280436.

Bland CM, Pai MP, Lodise TP. Reappraisal of Contemporary Pharmacokinetic and Pharmacodynamic Principles for Informing Aminoglycoside Dosing. Pharmacotherapy. 2018 Dec;38(12):1229-1238. doi: 10.1002/phar.2193. PubMed PMID: 30403305.

Lodise T, Corey R, Hooper D, Cammarata S. Safety of Delafloxacin: Focus on Adverse Events of Special Interest. Open Forum Infectious Diseases. 2018 Sep 10;5(10):ofy220. doi: 10.1093/ofid/ofy220. eCollection 2018 Oct. PubMed PMID: 30349845; PubMed Central PMCID: PMC6189306.

Bidell MR, Lodise TP. 中度肾功能损害患者使用新抗生素的次优临床反应率:文献综述和观察结果的潜在药代动力学和药效学考虑. Pharmacotherapy. 2018 Dec;38(12):1205-1215. doi: 10.1002/phar.2184. Epub 2018 Nov 9. PubMed PMID: 30289995.

Crass RL, Pai MP, Lodise TP Jr. 成人囊性纤维化患者哌拉西林/他唑巴坦个体化剂量:妥布霉素测量是否有帮助? Journal of Antimicrobial Chemotherapy 2019 Jan 1;74(1):126-129. doi: 10.1093/jac/dky388. PubMed PMID: 30252050.

Patel N, Huang D, Lodise T. 急性细菌性皮肤和皮肤结构感染住院患者使用伊克拉匹林避免万古霉素相关急性肾损伤的潜在成本节约. Clinical Drug Investigation 2018 Oct;38(10):935-943. doi: 10.1007/s40261-018-0686-5. PubMed PMID: 30105549.

Martin A, Fahrbach K, Zhao Q, Lodise T. Association Between Carbapenem Resistance and Mortality Among Adult, 肠杆菌科严重感染住院患者:系统文献综述和荟萃分析的结果. Open Forum Infectious Diseases 2018 Jun 28;5(7):ofy150. doi: 10.1093/ofid/ofy150. eCollection 2018 Jul. Review. PubMed PMID: 30046639; PubMed Central PMCID: PMC6054228. 

Zasowski EJ, Lodise TP. The Importance of Individualized Vancomycin Dosing to Ensure Optimal Exposure Early in Therapy. The Journal of Clinical Pharmacology 2018 Sep;58(9):1131-1133. doi: 10.1002/jcph.1281. Epub 2018 Jul 19. PubMed PMID: 30024648.

Butterfield-Cowper JM, Lodise TP Jr, Pai MP. A Fixed versus Weight-Based Dosing Strategy of Daptomycin May Improve Safety in Obese Adults. Pharmacotherapy 2018 Sep;38(9):981-985. doi: 10.1002/phar.2157. Epub 2018 July 12. PubMed PMID: 29906315.

Huang DB, Corey GR, Holland TL, Lodise T, O'Riordan W, Wilcox MH, File TM Jr, Dryden M, Balser B, Desplats E, Torres A. Pooled analysis of the phase 3 REVIVE trials: randomised, 评价伊克拉匹林与万古霉素治疗急性细菌性皮肤和皮肤结构感染的安全性和有效性的双盲研究. International Journal of Antimicrobial Agents 2018 Aug;52(2):233-240. doi: 10.1016/j.ijantimicag.2018.05.012. Epub 2018 May 19. PubMed PMID: 29783024.

Holland TL, O'Riordan W, McManus A, Shin E, Borghei A, File TM Jr, Wilcox MH, Torres A, Dryden M, Lodise T, Oguri T, Corey GR, McLeroth P, Shukla R, Huang DB. A Phase 3, Randomized, Double-Blind, 多中心研究评价静脉注射伊克拉匹林与万古霉素治疗怀疑或确认为革兰氏阳性病原体引起的急性细菌性皮肤和皮肤结构感染的安全性和有效性(REVIVE-2研究). Antimicrobial Agents and Chemotherapy 2018 Apr 26;62(5). pii: e02580-17. doi: 10.1128/AAC.02580-17. Print 2018 May. PubMed PMID: 29530858; PubMed Central PMCID: PMC5923167.

Hardalo C, Lodise TP, Bidell M, Flanagan S, De Anda C, Anuskiewicz S, Prokocimer P. 磷酸泰德唑胺治疗急性细菌性皮肤和皮肤结构感染的临床安全性和耐受性. Expert Opinion on Drug Safety 2018 Apr;17(4):359-367. doi: 10.1080/14740338.2018.1446939. Epub 2018 Mar 12. Review. PubMed PMID: 29528251.

McKinnell JA, Corman S, Patel D, Leung GH, Gordon LM, Lodise TP. 利用特拉万星治疗由金黄色葡萄球菌引起的医院获得性细菌性肺炎的有效抗菌药物管理策略. Clinical Therapeutics 2018 Mar;40(3):406-414.e2. doi: 10.1016/j.clinthera.2018.01.010. Epub 2018 Feb 15. PubMed PMID: 29454592.

Lodise TP, Bosso J, Kelly C, Williams PJ, Lane JR, Huang DB. 通过药代动力学和药效学分析确定伊克拉匹林治疗革兰氏阳性致病菌严重感染的最佳固定给药方案. Antimicrobial Agents and Chemotherapy 2018 Jan 25;62(2). pii: e01184-17. doi: 10.1128/AAC.01184-17. Print 2018 Feb. PubMed PMID: 29133566; PubMed Central PMCID: PMC5786772.

Luther MK, Timbrook TT, Caffrey AR, Dosa D, Lodise TP, LaPlante KL. Vancomycin Plus Piperacillin-Tazobactam and Acute Kidney Injury in Adults: A Systematic Review and Meta-Analysis. Critical Care Medicine 2018 Jan;46(1):12-20. doi: 10.1097/CCM.0000000000002769. Review. PubMed PMID: 29088001.

Lodise TP, Bidell M. Time to Evolve: Addressing the Challenge of CRE. Medscape http://www.medscape.org/viewarticle/894178.

医院重症细菌感染患者抗生素暴露-反应关系的定量评价.

我的工作重点是定量地提高我们目前对侵袭性细菌感染住院患者中抗菌药物暴露-反应关系的理解. 这些研究的目的是确定感染患者中与最大结果/最小毒性相关的抗生素暴露概况.

  • Lodise TP, Drusano GL, Zasowski E, Dihmess A, Lazariu V, Cosler L, McNutt LA. Vancomycin exposure in patients with MRSA bloodstream Infections: how much is enough? Clinical Infectious Diseases. 2014 Sep 1;59(5):666-75. PMID: 24867791.
  • Lodise TP, Patel N, Lomaestro BM, Rodvold KA, Drusano G. Relationship between Initial Vancomycin Concentration-Time Profile and Nephrotoxicity among Hospitalized Patients. Clinical Infectious Diseases 2009 Aug 15;49(4):507-14. PMID: 19586413.
  • van Hal SJ, Paterson DL, Lodise TP. 万古霉素引起的肾毒性与维持15至20毫克/升剂量表相关的系统评价和荟萃分析. Antimicrob Agents Chemother. 2013 Feb;57(2):734-44. doi: 10.1128/AAC.01568-12. Epub 2012 Nov 19. Review. PubMed PMID: 23165462; PubMed Central PMCID: PMC3553731.
  • Casapao AM, Lodise TP, Davis SL, Claeys KC, Kullar R, Levine DP, Rybak MJ. 耐甲氧西林金黄色葡萄球菌感染性心内膜炎患者万古霉素第1天暴露概况与预后的关系. Antimicrob Agents Chemother. 2015 Jun;59(6):2978-85. doi: 10.1128/AAC.03970-14.Epub 2015 Mar 9. PubMed PMID: 25753631; PubMed Central PMCID: PMC4432113.

Dose optimization of antibiotics in critically ill patients with invasive infections.

在过去的25年里，我们对抗生素暴露-反应关系的理解有了巨大的进步. For many antibiotics, the “pharmacodynamic” or the exposure variable associated with outcomes has been identified. 我已经将我们对抗菌药效学(PD)的理解应用到临床实践中，通过使用群体药代动力学建模和蒙特卡罗模拟，在专门的患者群体中设计经验性抗生素方案，这些方案有很高的概率实现与效果相关的PD目标.

  • Cardone KE, Chen WZ, Grabe DW, Batzold A, Manley HJ, Lodise TP. 自动腹膜透析患者常用静脉万古霉素给药方案的药效学评价. Journal Antimicrobial Chemotherapy. 2014 Jul;69(7):1873-6. PMID: 24722842.
  • Patel N, Scheetz MH, Drusano GL, Lodise TP. 住院患者传统输注和延长输注哌拉西林/他唑巴坦给药方案最佳肾脏剂量调整的确定. Antimicrobial Agents and Chemotherapy. 2010 Jan;54(1):460-5. Epub 2009 Oct 26. PMID: 19858253. PMCID: PMC2798531.
  • Butterfield JM, Mueller BA, Patel N, Cardone KE, Grabe DW, Salama NN, Lodise TP. Daptomycin pharmacokinetics and pharmacodynamics in a pooled sample of patients receiving thrice-weekly hemodialysis. Antimicrobial Agents and Chemotherapy. 2013 Feb;57(2):864-72. doi: 10.1128/AAC.02000-12. Epub 2012 Dec 3. PMID: 23208714. PMCID: PMC3553729.
  • Patel N, Pai MP, Rodvold KA, Lomaestro BM, Drusano GL, Lodise TP. Vancomycin: We Can’t Get There from Here. Clinical Infectious Diseases. 2011 Apr 15;52(8):969-74. PMID: 21460308.

Epidemiology and outcomes of hospitalized patients with infections due to antibiotic resistant bacteria.

抗生素耐药病原体引起的感染在过去二十年中急剧增加，是全世界住院患者的主要公共卫生威胁. Given the importance of early, appropriate therapy, my research focuses on the identification of patients at greatest risk for antibiotic infections. I also characterize the outcomes of patients with infections due to antibiotic resistant organisms.

  • Lodise TP, Drusano GL, Lazariu V, El-Fawal N, Evans A, Graffunder E, Stellrecht K, Mendes RE, Jones RN, Cosler L, McNutt LA. 量化万古霉素治疗的MRSA血流感染患者万古霉素敏感性表型降低与预后之间关系的矩阵 . J Antimicrob Chemother. 2014 Sep;69(9):2547-55. doi: 10.1093/jac/dku135. Epub 2014 May 19. PubMed PMID: 24840624.
  • Lodise TP, Graves J, Evans A, Graffunder E,  Helmecke M, Lomaestro BM, Stellrecht K.  Relationship between Vancomycin MIC and Failure among Patients with MRSA Bacteremia Treated with Vancomycin. Antimicrobial Agents and Chemotherapy 2008 Sep;52(9):3315-20. Epub 2008 Jun 30. PMID: 18591266. PMCID: PMC2533486.
  • Patel N, McNutt LA, Lodise TP. 铜绿假单胞菌引起的呼吸道感染患者不同抗生素暴露定义与哌哌西林-他唑巴坦耐药性的关系. Antimicrob Agents Chemother. 2008 Aug;52(8):2933-6. PubMed PMID: 18519718; PubMed Central PMCID: PMC2493121.
  • Lodise TP, Miller CD, Graves J, Furuno JP, McGregor JC, Lomaestro BM, Graffunder E, McNutt LA. 鉴别铜绿假单胞菌多重耐药风险最大的呼吸道感染患者的临床预测工具.  Antimicrobial Agents and Chemotherapy. 2007 Feb; 51(2):417-22. PMID: 17158943. PMCID: PMC1797724. 

药物流行病学和比较有效性研究，以确定抗生素耐药感染患者的最佳治疗策略.

Currently, 很少有完成的临床试验确定抗生素耐药感染患者的最佳治疗策略. 在确定抗生素耐药病原体引起的感染的最佳管理和治疗时，高度依赖“现实世界”的药物流行病学和比较有效性研究. Through the use of state of art study design and statistical modeling techniques, 我的研究使用真实世界的数据来确定最佳的治疗策略，最大限度地提高抗生素耐药感染患者的结果.     

  • Lodise TP, Lomaestro BM, Graves J, Drusano GL. Larger Vancomycin Doses are Associated with an Increased Incidence of Nephrotoxicity. Antimicrobial Agents and Chemotherapy 2008 Apr;52(4); 1330-6. Epub 2008  Jan 28. PMID: 18227177. PMCID: PMC2292536
  • Lodise TP, Lomaestro BM, Drusano GL. 哌拉西林/他唑巴坦治疗铜绿假单胞菌感染:延长输注剂量策略的临床意义. Clinical Infectious Diseases. 2007 Feb 1; 44(3):357-63. PMID: 17205441. 
  • Patel GW, Patel N, Lat A, Trombley K, Enbawe S, Manor K, Smith R, Lodise TP Jr. Outcomes of extended infusion piperacillin/tazobactam for documented Gram-negative infections. Diagn Microbiol Infect Dis. 2009 Jun;64(2):236-40. doi: 10.1016/j.diagmicrobio.2009.03.002. PubMed PMID: 19500529.
  • Lodise TP, McKinnon PS, Swiderski L, Rybak MJ. Outcomes analysis of delayed antibiotic treatment for hospital-acquired Staphylococcus aureus bacteremia. Clin Infect Dis. 2003 Jun 1;36(11):1418-23. Epub 2003 May 20. PubMed PMID: 12766837.

Conferences and Presentations

  • LaPensee K, Lodise T. 在接受莫西沙星治疗有艰难梭菌感染风险的住院社区获得性肺炎患者中使用奥马达环素的成本节约分析:预算影响模型结果. ASHP Midyear Clinical Meeting, Anaheim CA, December 2-6, 2018. Poster #4-049. Presenter: LaPensee.
  • LaPensee K, Lodise T. Cost-saving Opportunities Among Hospitalized Community-Acquired Pneumonia Patients Treated with Omadacycline, an Aminomethylcycline Antibiotic with IV and Oral Formulations, Compared to Ceftriaxone and Macrolide Therapy. ASHP Midyear Clinical Meeting, Anaheim CA, December 2-6, 2018. Poster #4-048. Presenter: LaPensee.
  • Lodise T, LaPensee K. 应用头孢曲松和大环内酯类药物治疗社区获得性细菌性肺炎成人患者肺炎严重程度指数评分的住院模式. IDweek2018, San Francisco CA, October 3-7, 2018. Abstract #1462. Presenter: Lodise.
  • Patel N, Clark J, Stornelli N, Belfiore G, Lodise TP. 退伍军人社区获得性细菌性肺炎患者氟喹诺酮类药物与头孢曲松/阿奇霉素治疗组跟腱不良事件的比较评价. IDweek2018, San Francisco CA, October 3-7, 2018. Abstract #1463. Presenter: Patel.
  • Puzniak L, Fu R, Gundrum J, Lodise TP. 美国253家医院接受头孢唑烷/他唑巴坦治疗的患者特征和结果的真实世界评估. IDweek2018, San Francisco CA, October 3-7, 2018. Abstract # 2414. Presenter: Lodise.
  • Lodise T, Packnett E, Armstrong S, Redell M. 在门诊接受奥利塔万星(ORI)或万古霉素(VAN)治疗皮肤感染的患者30天入院和30天总医疗费用的比较. IDweek2018, San Francisco CA, October 3-7, 2018. Abstract # 1928. Presenter: Lodise.
  • Lodise TP, Bonine NG, Ye JM, Folse HJ, Gillard P. 一种床边工具的开发，以预测成人革兰氏阴性感染人群中耐药病原体的概率. IDweek2018, San Francisco CA, October 3-7, 2018. Abstract # 1166. Presenter: Lodise.
  • Saade E, Wilson B, El Chakhtoura NG, Viau R, Perez F, Lodise T, Bonomo RA. Drug-Induced Liver Injury (DILI) in a National Cohort of Hospitalized Patients treated with Aztreonam and Ceftazidime. IDweek2018, San Francisco CA, October 3-7, 2018. Abstract # 2409. Presenter: Saade.
  • Cai B, Echols R, Corvino R, Lodise TP. Epidemiology and Outcomes of Patients with Carbapenem-Resistant Bloodstream Infection in United States (US) Hospitals, 2010-2015. IDweek2018, San Francisco CA, October 3-7, 2018. Abstract # 681. Presenter: Echols.
  • Lodise TP, Smith NM, Holden P, O'Donnell JN, Bedard T, Bonomo RA, Tsuji BT. 头孢他啶-阿维巴坦联合氨曲南(COMBINE)对产金属β-内酰胺酶肠杆菌科(MBL)的疗效. IDweek2018, San Francisco CA, October 3-7, 2018. Abstract # 1385. Presenter: Tsuji.
  • Avedissian S, Liu J, O'Donnell JN, Pais G, Becher L, Joshi M, Prozialeck W, Lamar P, Lodise TP, Scheetz MH. Poster presentation at IDweek2018™. San Francisco, CA. October 3-7, 2018. Abstract # 1419. Presenter: Avedissian.
  • Rank E, Lodise TP, Avery L, Bankert E, Dobson E, Dumyati G, Hassett S, Keller M, Lubowski T, Pearsall M, Carreno J. 纽约州门诊区域尿路病原体抗生素图:我们已经达到了后抗生素时代治疗尿路感染? IDweek2018, San Francisco CA, October 3-7, 2018. Abstract # 1237. Presenter: Carreno.
  • Huang D, Corey RG, Holland TL, Lodise TP, O'Rirodan W, Wilcox M, File TM, Dryden M, Torres A, Balser B, Desplats E. A Pooled Analysis of Patients with Wound Infections in the Phase 3 REVIVE Trials: Randomized, 评价伊克拉匹林与万古霉素治疗急性细菌性皮肤和皮肤结构感染的安全性和有效性的双盲研究. IDweek2018, San Francisco CA, October 3-7, 2018. Abstract # 1338. Presenter: Huang.
  • Shorr A, Lodise T, Echols R, Wang W, Corvino FA, B. Cai B, Zilberberg M. 美国医院血液感染中6种革兰氏阴性病原体碳青霉烯耐药性的流行及微生物学分析, 2010-2015. IDweek2018, San Francisco CA, October 3-7, 2018. Abstract # 1191. Presenter: Echols.
  • Patel N, Sangiovanni R, Stornelli N, Amin R, Huang D, Lodise TP. 退伍军人皮肤及皮肤结构感染患者万古霉素相关性急性肾损伤发生率及医疗保健利用. 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Madrid Spain, April 21-24, 2018. ePoster viewing #E0283. Presenter: Patel.
  • Tartof S, Kuntz J, Chen L, Wei R, Puzniak L, Tian Y, Im T, Takhar H, Merchan S, Lodise TP. 预测成人碳青霉烯不敏感和泛-内酰胺不敏感可能性的临床风险评分, hospitalized patients with infections due to Pseudomonas aeruginosa. 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Madrid Spain, April 21-24, 2018. Oral flash #O0130. Presenter: Lodise.
  • Patel N, Huang D, Lodise T. 与万古霉素(VAN)相比，靶向伊克拉匹林(ICL)在急性细菌性皮肤和皮肤结构感染性住院患者中的潜在成本节约机会，因为可能避免与VAN相关的急性肾损伤. 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Madrid Spain, April 21-24, 2018. Paper poster #P0283. Presenter: Patel.
  • Crass R, Lodise T, Pai M. 成人囊性纤维化患者哌拉西林/他唑巴坦个体化剂量:妥布霉素测量是否有帮助? 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Madrid Spain, April 21-24, 2018. Paper poster #P0868. Presenter: Crass.

Extramural Grants

Role: Principal Investigator
项目名称:一项在健康年轻人中评估AVYCAZ®联合氨曲南(COMBINE)安全性和药代动力学的i期研究
Grantor: Sub-award through Duke University; Primary sponsor: National Institute of Allergy and Infectious Diseases
Amount at ACPHS: $90,000
Grant Number: 1UM1AI104681-06
Term: 11/01/2018 – 12/31/2018

Role: Co-Investigator (PI: Richard Wunderlink, MD)
项目名称:危重成人单次输注注射用米诺环素的开放标签药代动力学研究(Acumin)
Grantor: Sub-award through Duke University; Primary sponsor: National Institute of Allergy and Infectious Diseases
Grant Number: 1UM1AI104681-01 
Amount at ACPHS: $48,000
Term: 11/01/18 - 12/31/18

Role: Chair (PI: Vance Fowler, MD)
Project Title: PK ARLG Steering Committee Chair
Grantor: Sub-award through Duke University; Primary sponsor: National Institute of Allergy and Infectious Diseases
Grant Number: 1UM1AI104681-01 
Amount at ACPHS: $342,000
Term: 1/01/18- 12/31/18 


ALBANY CAMPUS
REQUEST INFO
APPLY NOW